ATL 101 companion diagnostic - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals

Drug Profile

ATL 101 companion diagnostic - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals

Alternative Names: 68Ga-HBED-CC-PSMA - Advanced Nuclear Medicine Ingredients; 68Ga-PSMA-11 - Advanced Nuclear Medicine Ingredients; TLX-591 companion diagnostic - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Nuclear Medicine Ingredients
  • Developer Advanced Nuclear Medicine Ingredients; Telix Pharmaceuticals
  • Class Antineoplastics; Diagnostic agents; Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Prostate cancer

Most Recent Events

  • 24 Oct 2017 Early research in Prostate cancer (Metastatic disease) in Australia (Injection)
  • 24 Oct 2017 Advanced Nuclear Medicine Ingredients and Telix Pharmaceuticals agree to develop and commecialise ATL 101 companion diagnostic (68Ga-PSMA-11) worldwide for Prostate cancer
  • 24 Oct 2017 Early research in Prostate cancer (Metastatic disease) in Belgium (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top